|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a major cause of cancer-related mortality for which liver resection is an important curative-intent treatment option. However, many patients present with advanced disease and with underlying chronic liver disease and/or cirrhosis, limiting the proportion of patients who are surgical candidates. In addition, the development of recurrent or de novo cancers following surgical resection is common. These issues have led investigators to evaluate the benefit of neoadjuvant and adjuvant treatment strategies aimed at improving resectability rates and decreasing recurrence rates. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC. In this review, we evaluate the evidence for various neoadjuvant and adjuvant therapies and discuss opportunities for future clinical and translational research. | Clifford Akateh Sylvester M Black Lanla Conteh Eric D Miller Anne Noonan Eric Elliott Timothy M Pawlik Allan Tsung Jordan M Cloyd | 2019 | World Journal of Gastroenterology2019，25，28： | 16 |
| 2 | Management of borderline and locally advanced pancreatic cancer:Where do we stand?显示文摘Many patients with pancreas cancer present with locally advanced pancreatic cancer(LAPC).The principle tools used for diagnosis and staging of LAPC include endoscopic ultrasound,axial imaging with computed tomography and magnetic resonance imaging,and diagnostic laparoscopy.The definition of resectability has historically been vague,as there is considerable debate and controversy as to the definition of LAPC.For the patient with LAPC,there is some level of involvement of the surrounding vascular structures,which include the superior mesenteric artery,celiac axis,hepatic artery,superior mesenteric vein,or portal vein.When feasible,most surgeons would recommend possible surgical resection for patients with borderline LAPC,with the goal of an R0 resection.For initially unresectable LAPC,neoadjuvant should be strongly considered.Specifically,these patients should be offered neoadjuvant therapy,and the tumor should be assessed for possible response and eventual resection.The efficacy of neoadjuvant therapy with this approach as a bridge to potential curative resection is broad,ranging from 3%-79%.The different modalities of neoadjuvant therapy include sin-gle or multi-agent chemotherapy combined with radiation,chemotherapy alone,and chemotherapy followed by chemotherapy with radiation.This review focuses on patients with LAPC and addresses recent advances and controversies in the field. | Jin He Andrew J Page Matthew Weiss Christopher L Wolfgang Joseph M Herman Timothy M Pawlik | 2014 | World Journal of Gastroenterology2014，20，9： | 11 |
| 3 | Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery显示文摘According to the United States census bureau 20% of Americans will be older than 65 years in 2030 and half of them will need an operation- equating to about 36 million older surgical patients. Older adults are prone to complications during gastrointestinal cancer treatment and therefore may need to undergo special pretreatment assessments that incorporate frailty and sarcopenia assessments. A focused, structured literature review on Pub Med and Google Scholar was performed to identify primary research articles, review articles, as well as practice guidelines on frailty and sarcopenia among patients undergoing gastrointestinal surgery. The initial search identified 450 articles; after eliminating duplicates, reports that did not include surgical patients, case series, as well as case reports, 42 publications on the impact of frailty and/or sarcopenia on outcome of patients undergoing gastrointestinal surgery were included. Frailty is defined as a clinically recognizable state of increased vulnerability to physiologic stressors resulting from aging. Frailty is associated with a decline in physiologic reserve and function across multiple physiologic systems. Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength. Unlike cachexia, which is typically associated with weight loss due to chemotherapy or a general malignancy-related cachexia syndrome, sarcopenia relates to muscle mass rather than simply weight. As such, while weight reflects nutritional status, sarcopenia- the loss of muscle mass- is a more accurate and quantitative global marker of frailty. While chronologic age is an important element in assessing a patient's peri-operative risk, physiologic age is a more important determinant of outcomes. Geriatric assessment tools are important components of the preoperative work-up and can help identify patients who suffer from frailty. Such data are important, as frailty and sarcopenia have repeatedly been demonstrated among the strongest predictors of both short- and longterm outcome following complicated surgical procedures such as esophageal, gastric, colorectal, and hepatopancreatico-biliary resections. | doris wagner mara mcadams demarco neda amini stefan buttner dorry segev faiz gani timothy m pawlik | 2016 | World Journal of Gastrointestinal Surgery2016，8，1： | 8 |
| 4 | Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma显示文摘Intrahepatic cholangiocarcinoma(ICC)is the second most common primary liver malignancy and is increasing in incidence.Long-term outcomes are optimized when patients undergo margin-negative resection followed by adjuvant chemotherapy.Unfortunately,a significant proportion of patients present with locally advanced,unresectable disease.Furthermore,recurrence rates are high even among patients who undergo surgical resection.The delivery of systemic and/or liver-directed therapies prior to surgery may increase the proportion of patients who are eligible for surgery and reduce recurrence rates by prioritizing early systemic therapy for this aggressive cancer.Nevertheless,the available evidence for neoadjuvant therapy in ICC is currently limited yet recent advances in liver directed therapies,chemotherapy regimens,and targeted therapies have generated increasing interest its role.In this article,we review the rationale for,current evidence for,and ongoing research efforts in the use of neoadjuvant therapy for ICC. | Clifford Akateh Aslam M Ejaz Timothy Michael Pawlik Jordan M Cloyd | 2020 | World Journal of Hepatology2020，12，10： | 8 |
| 5 | Surgery for colorectal liver metastases: The evolution of determining prognosis显示文摘Despite improvements in the multi-modality treatment of colorectal liver metastasis (CRLM), survival after resection remains varied. Determining prognosis after surgical resection has historically been predicated on preoperative clinicopathological factors such as primary tumor stage, carcinoembryonic antigen levels, number of liver metastases, presence of extrahepatic disease, as well as other factors. While scoring systems have been developed by combining certain preoperative fac- tors, these have been inconsistent in accurately deter- mining prognosis. There has been increasing interest in the use of biologic and molecular markers to predict prognosis following CRLM. The role of markers such as KRAS, BRAF, p53, human telomerase reverse transcrip- tase, thymidylate synthase, Ki-67, and hypoxia inducible factor-1α and their correlation with accurately predict- ing survival after surgical resection have been sup- ported by several studies. Furthermore, other elements such as pathological response to chemotherapy and the presence of circulating tumor cells have shown promise in accurately determining prognosis after resection for colorectal liver metastasis.We herein review past, present, and possible future markers of prognosis among colorectal cancer patients with liver metastasis undergo-ing resection with curative intent. | Gaya Spolverato Aslam Ejaz Nilo Azad Timothy M Pawlik | 2013 | World Journal of Gastrointestinal Oncology2013，5，12： | 7 |
| 6 | Textbook outcomes in hepatobiliary and pancreatic surgery显示文摘The concept of textbook outcome (TO) has recently gained popularity in surgicalresearch and has been used to evaluate the quality or success of different surgicalprocedures, including hepatopancreatobiliary (HPB) operations. TO consists ofindividual outcome parameters that each reflect different domains of careincluding structure, process, and individual outcomes;in turn, the composite TOmetric represents the optimal course after a surgical episode. TO can be used toassess patient-level outcomes, hospital performance, center designation andquality metrics. In addition to being an outcome measurement, TO may also belinked to healthcare costs. Future efforts should be directed towards establishing auniversal definition of TO in HPB surgery so that surgeons and hospitals canassess and compare outcomes, identify shortcomings and improve real worldpatient outcomes. | Diamantis I Tsilimigras Timothy Michael Pawlik Dimitrios Moris | 2021 | World Journal of Gastroenterology2021，27，15： | 6 |
| 7 | 脾切除对病毒性肝炎肝硬化合并门静脉高压症患者肝癌发生影响的多中心队列研究显示文摘目的探讨脾切除术对肝硬化合并门静脉高压症患者发生肝细胞癌(HCC)的影响。方法回顾性收集2008年1月至2012年12月中国7所三级医院收治的因肝硬化和门静脉高压症继发脾功能亢进行脾切除术的407例患者的病例资料,纳入脾切除组;将同期因肝硬化和门静脉高压症接受药物治疗的464例患者的病例资料纳入非脾切除组。脾切除术中采用开腹或腹腔镜联合或不联合贲门血管离断术。非脾切除组中所有患者均在HCC发生前保守治疗肝硬化和门静脉高压症,未进行经颈静脉肝内门体分流术、脾切除或肝移植术。两组患者均采用相同的HCC监测方案。每3~6个月常规进行腹部超声检查、肝功能检查和甲胎蛋白检查。使用倾向性评分匹配(PSM)对脾切除组和非脾切除组的患者资料进行匹配。采用Kaplan-Meier法计算总体生存率和肝癌累积发生率,采用对数秩和检验比较两组患者的生存率。采用单因素和Cox比例风险回归模型分析影响肝癌发生的相关因素。结果PSM后,两组各233例患者。49例(12.0%)脾切除患者和75例(16.2%)非脾切除患者在随访期间发生了HCC。脾切除组患者1、3、5、7年HCC的累积发生率分别为1%、6%、7%、15%,显著低于非脾切除组1%、6%、15%、23%(HR=0.53,95%CI:0.31~0.91,P=0.028)。多因素分析结果显示,年龄≤40岁、男性、有脾切除史是HCC发生的独立相关因素(HR=0.55,95%CI:0.32~0.95,P=0.031)。脾切除组1、3、5、7年累积生存率分别为100%、97%、91%、86%,而非脾切除组为100%、97%、92%、84%,差异无统计学意义(P=0.899)。与非脾切除组的HCC患者相比,脾切除组发生HCC患者接受肝切除的比例更低(12.2%比33.3%,χ^(2)=7.029,P=0.008)。结论脾切除术可能降低肝硬化合并门静脉高压症患者HCC的发病风险。 | 张谞丰 刘阳 李建辉 雷鹏 张兴元 万真 雷霆 张楠 武晓宁 龙志达 李宗芳 王博 刘学民 仵正 陈熹 王健雄 袁鹏 李勇 周军 Pawlik Timothy M. 吕毅 | 2021 | 中华外科杂志2021，59，10： | 5 |
| 8 | Selection for hepatic resection of colorectal liver metastases: expert consensus statement显示文摘 | Reid B. Adams Thomas A. Aloia Evelyne Loyer Timothy M. Pawlik Bachir Taouli Jean‐Nicolas Vauthey | 2013 | HPB2013，，2： | 3 |
| 9 | Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer显示文摘 | Timothy M. Pawlik Ana L. Gleisner John L. Cameron Jordan M. Winter Lia Assumpcao Keith D. Lillemoe Christopher Wolfgang Ralph H. Hruban Richard D. Schulick Charles J. Yeo Michael A. Choti | 2007 | Surgery2007，，5： | 3 |
| 10 | Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma显示文摘 | John Bridgewater Peter R. Galle Shahid A. Khan Josep M. Llovet Joong-Won Park Tushar Patel Timothy M. Pawlik Gregory J. Gores | 2014 | Journal of Hepatology2014，，6： | 3 |
| 11 | Debunking dogma: Surgery for four or more colorectal liver metastases is justified显示文摘 | Timothy M. Pawlik M.D. M.P.H. Eddie K. Abdalla M.D. Lee M. Ellis M.D. Jean-Nicolas Vauthey M.D. Steven A. Curley M.D | 2006 | Journal of Gastrointestinal Surgery2006，，2： | 2 |
| 12 | Pancreatic Resection of Isolated Metastases from Nonpancreatic Primary Cancers显示文摘 | Sushanth Reddy MD Barish H. Edil MD John L. Cameron MD Timothy M. Pawlik MD MPH Joseph M. Herman MD Marta M. Gilson PhD Kurtis A. Campbell MD Richard D. Schulick MD Nita Ahuja MD Christopher L. Wolfgang MD PhD | 2008 | Annals of Surgical Oncology2008，，11： | 2 |
| 13 | Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases显示文摘 | Daria Zorzi M.D. John T. Mullen M.D. Eddie K. Abdalla M.D. Timothy M. Pawlik M.D. M.P.H. Axel Andres M.D. Andrea Muratore M.D. Steven A. Curley M.D. Gilles Mentha M.D. Lorenzo Capussotti M.D. Jean-Nicolas Vauthey M.D | 2006 | Journal of Gastrointestinal Surgery2006，，1： | 2 |
| 14 | Neoadjuvant chemotherapy for colorectal liver metastases:A contemporary review of the literature显示文摘Colorectal carcinoma(CRC)is one of the leading causes of cancer-related deaths worldwide,and up to 50%of patients with CRC develop colorectal liver metastases(CRLM).For these patients,surgical resection remains the only opportunity for cure and long-term survival.Over the past few decades,outcomes of patients with metastatic CRC have improved significantly due to advances in systemic therapy,as well as improvements in operative technique and perioperative care.Chemotherapy in the modern era of oxaliplatin-and irinotecancontaining regimens has been augmented by the introduction of targeted biologics and immunotherapeutic agents.The increasing efficacy of contemporary systemic therapies has led to an expansion in the proportion of patients eligible for curative-intent surgery.Consequently,the use of neoadjuvant strategies is becoming progressively more established.For patients with CRLM,the primary advantage of neoadjuvant chemotherapy(NCT)is the potential to down-stage metastatic disease in order to facilitate hepatic resection.On the other hand,the routine use of NCT for patients with resectable metastases remains controversial,especially given the potential risk of inducing chemotherapy-associated liver injury prior to hepatectomy.Current guidelines recommend upfront surgery in patients with initially resectable disease and low operative risk,reserving NCT for patients with borderline resectable or unresectable disease and high operative risk.Patients undergoing NCT require close monitoring for tumor response and conversion of CRLM to resectability.In light of the growing number of treatment options available to patients with metastatic CRC,it is generally agreed that these patients are best served at tertiary centers with an expert multidisciplinary team. | Marissa Guo Ning Jin Timothy Pawlik Jordan M Cloyd | 2021 | World Journal of Gastrointestinal Oncology2021，13，9： | 2 |
| 15 | Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study显示文摘 | Charles C. Hsu MD PhD Joseph M. Herman MD MSc Michele M. Corsini MD Jordan M. Winter MD Matthew D. Callister MD Michael G. Haddock MD John L. Cameron MD Timothy M. Pawlik MD MPH Richard D. Schulick MD Christopher L. Wolfgang MD PhD Daniel A. Laheru MD | 2010 | Annals of Surgical Oncology2010，，4： | 2 |
| 16 | Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database显示文摘 | Kelvin K. Ng Jean-Nicolas Vauthey Timothy M. Pawlik Gregory Y. Lauwers Jean-Marc Regimbeau Jacques Belghiti Iwao Ikai Yoshio Yamaoka Steven A. Curley David M. Nagorney Irene O. Ng Sheung Tat Fan Ronnie T. Poon | 2005 | Annals of Surgical Oncology2005，，5： | 2 |
| 17 | Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: Results of a multicenter study显示文摘 | Timothy M. Pawlik Ronnie T. Poon Eddie K. Abdalla Iwao Ikai David M. Nagorney Jacques Belghiti Reza Kianmanesh Irene Oi-Lin Ng Steven A. Curley Yoshio Yamaoka Gregory Y. Lauwers Jean-Nicolas Vauthey | 2005 | Surgery2005，，4： | 2 |
| 18 | Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease显示文摘 | Timothy M. Pawlik MD MPH Daria Zorzi MD Eddie K. Abdalla MD Bryan M. Clary MD Jeffrey E. Gershenwald MD Merrick I. Ross MD Thomas A. Aloia MD Steven A. Curley MD Luis H. Camacho MD MPH Lorenzo Capussotti MD Dominique Elias MD Jean-Nicolas Vauthey MD | 2006 | Annals of Surgical Oncology2006，，5： | 2 |
| 19 | A Risk Model to Predict 90-Day Mortality among Patients Undergoing Hepatic Resection显示文摘 | Omar Hyder Carlo Pulitano Amin Firoozmand Rebecca Dodson Christopher L. Wolfgang Michael A. Choti Luca Aldrighetti Timothy M. Pawlik | 2013 | Journal of the American College of Surgeons2013，，6： | 2 |
| 20 | Is Extended Hepatectomy for Hepatobiliary Malignancy Justified?显示文摘 | Jean-Nicolas Vauthey Timothy M. Pawlik Eddie K. Abdalla James F. Arens Rabih A. Nemr Steven H. Wei Debra L. Kennamer Lee M. Ellis Steven A. Curley | 2004 | Annals of Surgery2004，，5： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员